Pharmaceutical start-up AcadeMab Biomedical Inc (研生生醫) said it has been developing a COVID-19 antibody drug, an endeavor not being undertaken by many other Taiwanese pharmaceutical firms.
The company was spun off from Academia Sinica’s Institute of Cellular and Organismic Biology in 2020 and has only 16 employees. It has set its sights on the innovative field of the monoclonal antibody treatment of tumors.
The start-up began developing antibody drugs in January, after seeing that COVID-19 vaccines could not effectively protect people from new variants of SARS-CoV-2, AcadeMab Biomedical chief strategy officer Pearl Fong (俸清珠) said in an interview with the Taipei Times on Thursday.
Photo courtesy of AcadeMab Biomedical Inc
The development of COVID-19 antibody drugs focuses on the sequences of the antibodies produced in the body following vaccination, Fong said.
The method does not require any information on the sequences of SARS-CoV-2, she said.
“Specifically, we need to know the DNA sequences of the Y-shaped antibodies carried by people’s memory B cells. Once we obtain the sequences, we can replicate the antibodies,” she added.
The start-up for at least four weeks collected blood samples from five people who had received three doses of COVID-19 vaccines. It then used a method called “cell shorting” to isolate memory B cells and used genetic engineering to decode the sequences of the antibody, AcadeMab Biomedical project manager Chiang Pao-yin (姜伯穎) said.
Getting the right sequences was not easy, Chiang said.
A 20 to 30 milliliter blood sample contains about 40 million cells, from which about 100,000 memory B cells can be isolated, Chiang said.
Using advanced technology, the company initially obtained about 2,000 sequences of antibodies and selected 163 that were expected to be the most effective in fighting against SARS-CoV-2 variants, he said.
“It is like making a key. It must not only have the right shape to fit in the hole, but it also has to be long enough to be used. The right antibodies must not only bind with the spike protein of the virus, but bind firmly,” Chiang said.
The start-up selected 10 sequences and tested them against the Omicron subvariants of SARS-CoV-2 and eventually chose four that showed the most potential, Chiang said, adding that its experimental drug is called SB-001.
Explaining how antibody drugs fight against new SARS-CoV-2 variants while vaccines cannot, Fong said that vaccines and antibody drugs use different mechanisms.
Vaccines prompt the immune system to produce antibodies, but after a given period, only a few antibodies that are most effective against a variant remain in the body, Fong said.
However, it is possible that these antibodies cannot attack new subvariants, she said.
Developers of COVID-19 antibody drugs have deep knowledge of antibody sequences, Fong said.
“It’s like we have a database. We can always research which sequence works best against the latest subvariant and change our formula accordingly,” Fong said.
An antibody that does not work well against an older subvariant could be effective against a new subvariant, she added.
“That has been the case with Eli Lilly and Co. Its first two antibody drugs were approved, but they did not work against later Omicron subvariants. However, the company found another sequence and used it to develop a new antibody drug,” Fong said.
AcadeMab Biomedical is one of only a few Taiwanese companies working on COVID-19 antibody drugs, she said.
Fong said there are two reasons that Taiwanese companies prefer to develop COVID-19 vaccines over antibody drugs, with about 10 firms working on vaccines.
“First, vaccines use fewer proteins than antibody drugs, so vaccine developers can conduct research more easily with limited manufacturing capacity. Second, the requirements for clinical trials involving antibody drugs are much stricter than those for vaccines,” she said.
Antibody drugs are mainly used for treatment instead of prevention, Fong said, adding that they can be used for prevention in some cases, she said.
People who are planning to travel to high-risk areas could take the drugs before embarking on their trip, she said.
As AcadeMab Biomedical focuses on research, it plans to find a manufacturing partner to codevelop SB-001, Fong said, adding that the company has been in talks with several firms and hopes to finalize a deal by the end of this year.
It plans to apply for emergency use authorization in the US and hopes to start phase 1 human trials by June next year, she said.
DECOUPLING? In a sign of deeper US-China technology decoupling, Apple has held initial talks about using Baidu’s generative AI technology in its iPhones, the Wall Street Journal said China has introduced guidelines to phase out US microprocessors from Intel Corp and Advanced Micro Devices Inc (AMD) from government PCs and servers, the Financial Times reported yesterday. The procurement guidance also seeks to sideline Microsoft Corp’s Windows operating system and foreign-made database software in favor of domestic options, the report said. Chinese officials have begun following the guidelines, which were unveiled in December last year, the report said. They order government agencies above the township level to include criteria requiring “safe and reliable” processors and operating systems when making purchases, the newspaper said. The US has been aiming to boost domestic semiconductor
Nvidia Corp earned its US$2.2 trillion market cap by producing artificial intelligence (AI) chips that have become the lifeblood powering the new era of generative AI developers from start-ups to Microsoft Corp, OpenAI and Google parent Alphabet Inc. Almost as important to its hardware is the company’s nearly 20 years’ worth of computer code, which helps make competition with the company nearly impossible. More than 4 million global developers rely on Nvidia’s CUDA software platform to build AI and other apps. Now a coalition of tech companies that includes Qualcomm Inc, Google and Intel Corp plans to loosen Nvidia’s chokehold by going
ENERGY IMPACT: The electricity rate hike is expected to add about NT$4 billion to TSMC’s electricity bill a year and cut its annual earnings per share by about NT$0.154 Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) has left its long-term gross margin target unchanged despite the government deciding on Friday to raise electricity rates. One of the heaviest power consuming manufacturers in Taiwan, TSMC said it always respects the government’s energy policy and would continue to operate its fabs by making efforts in energy conservation. The chipmaker said it has left a long-term goal of more than 53 percent in gross margin unchanged. The Ministry of Economic Affairs concluded a power rate evaluation meeting on Friday, announcing electricity tariffs would go up by 11 percent on average to about NT$3.4518 per kilowatt-hour (kWh)
OPENING ADDRESS: The CEO is to give a speech on the future of high-performance computing and artificial intelligence at the trade show’s opening on June 3, TAITRA said Advanced Micro Devices Inc (AMD) chairperson and chief executive officer Lisa Su (蘇姿丰) is to deliver the opening keynote speech at Computex Taipei this year, the event’s organizer said in a statement yesterday. Su is to give a speech on the future of high-performance computing (HPC) in the artificial intelligence (AI) era to open Computex, one of the world’s largest computer and technology trade events, at 9:30am on June 3, the Taiwan External Trade Development Council (TAITRA) said. Su is to explore how AMD and the company’s strategic technology partners are pushing the limits of AI and HPC, from data centers to